9. Humulin

Humulin's sales growth measured a substantial 13% in the U.S.

Company: Eli Lilly
2016 U.S. sales: $862 million
Drug class: Human insulin

Eli Lilly’s Humulin has been around for a long, long time, but it’s still pumping out sales growth. In 2016, that sales growth measured a substantial 13% in the U.S.

The reasons? Demand for the Indianapolis drugmaker’s product increased, it said, and that was the primary driver. But Lilly also benefitted from higher net prices, thanks to a change in the estimate of a government rebate in the first quarter of last year.

For a long time, Lilly kept the growth coming with list price increases on its elderly and long-off-patent med. Between 2007 and 2013, Humulin’s price leapt by 354%, offsetting payer pressure and the termination of an agreement with Walmart.

After taking a 17.5% price hike on Humulin in 2015, however, Lilly cut its increase by more than half to 7.5% in 2016, according to Wells Fargo analyst David Maris. And as of late January of this year, the company had yet to take one at all.

9. Humulin

Suggested Articles

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.

A top adviser for the Trump administration is calling on Congress to push for more manufacturing in Puerto Rico.